HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance

HeartBeam

13/08/2026 21:12

Overview
U.S. cardiac device maker's Q2 net loss nearly flat yr/yr, loss per share narrows
Company lowered expected full yr 2026 net operating cash outflow below $14.0 mln
Completed pilot study enrollment ahead of schedule, launched HeartBeam System, developed ECG patch prototype

Outlook
Company expects Q3 2026 cash outflow in line with Q2 2026
Baseline Q4 2026 operating cash outflow expected to fall below $2.5 mln
Company lowers full-year 2026 net operating cash outflow guidance to below $14.0 mln

Result Drivers
CLINICAL PROGRAM PROGRESS - Co completed enrollment in ALIGN-ACS heart attack detection study and surpassed 50% enrollment in Indonesian pilot ahead of schedule, with data analysis underway
COMMERCIAL LAUNCH ADVANCEMENT - Initial commercial launch of HeartBeam System underway with multiple agreements signed and first orders shipped across four U.S. regions
R&D EXPENSE DECLINE - Lower research and development expenses driven by reduced product development and consulting costs related to HeartBeam System

Company press release: ID:nBw1Mk4bfa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.10
 
Q2 Net Loss
 
$5.04 mln
 
Q2 Income From Operations
 
-$5.09 mln
 
Q2 Loss Per Basic Share
 
$0.10
 
Q2 Operating Expenses
 
$5.09 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for HeartBeam, Inc. is $3.25, about 468.2% above its August 12 closing price of $0.57

Reuters Recommended Reads
Aug 12 - BioCardia Q2 net loss narrows on lower R&D costs
Aug 11 - Stereotaxis Q2 revenue misses estimates, dragged by system decline
Aug 12 - Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)